Group 1 - The vitamin sector has seen a rise of 2.34%, ranking 9th among concept sectors, with 62 stocks increasing in value [1][2] - Notable gainers include Nonnawell, Fengyuan Pharmaceutical, and Nengte Technology, which reached the daily limit, while Minsheng Health, Zhenhua Co., and Erkang Pharmaceutical also showed significant increases of 8.75%, 7.15%, and 6.69% respectively [1][2] - The sector experienced a net inflow of 5.92 billion yuan from main funds, with 43 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2][3] Group 2 - The top stocks by net inflow include Nonnawell with 925.69 million yuan, followed by Fengyuan Pharmaceutical with 884.21 million yuan, and Zhongsheng Pharmaceutical with 728.46 million yuan [2][3] - The net inflow ratios for Fengyuan Pharmaceutical, Nengte Technology, and Huate Dain are 24.78%, 19.08%, and 14.28% respectively, indicating strong investor interest [3] - Stocks such as Dongbao Biological, Huate Dain, and Huaheng Biological experienced declines of 3.71%, 2.04%, and 0.91% respectively, highlighting some volatility within the sector [1][5]

证券代码：002940 证券简称：昂利康 公告编号：2025-048 一、股票交易异常波动的情况介绍 浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）股票（证 券代码：002940，证券简称：昂利康）连续 3 个交易日（2025 年 6 月 27 日、2025 年 6 月 30 日、2025 年 7 月 1 日）收盘价格涨幅偏离值累计超过 20%，根据《深 圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动情况，公司董事会对有关事项进行了核查，有关 情况说明如下： 1、公司前期披露的信息不存在需要更正或补充披露的事项； 2、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 浙江昂利康制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 6、公司关注到近期市场对创新药业务关注度较高。公司目前在研的创新药 项目仅有一个，系 ALK-N001 项目，该项目于 2025 年 4 月获得药物临床试验批 1 准通知书，截至 ...

关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上 刊载的《关于回购公司股份方案暨收到<贷款承诺书>的公告》（公告编号： 2024-075）、《回购股份报告书》（公告编号：2024-077）。 一、回购进展情况 截至 ...

Market Overview - The market experienced fluctuations with mixed performance across the three major indices, with a total trading volume of 1.49 trillion [1] - The innovative drug sector saw a resurgence, with stocks like Angli康 and塞力医疗 hitting the daily limit [1] - Chip stocks continued their strong performance, with companies such as诚邦股份 and凯美特气 also reaching the daily limit [1] - Bank stocks rebounded, with建设银行 and浦发银行 reaching historical highs [1] - The military industry showed localized activity, with stocks like长城军工 and际华集团 hitting the daily limit [1] - Stablecoin concept stocks declined, with吉大正元 hitting the daily limit down [1] Key Highlights Pharmaceutical Sector - The pharmaceutical sector rebounded significantly, with昂立康 hitting the daily limit and reaching a historical high [3] - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, including increased support for R&D and inclusion in insurance directories [3][4] - Companies like阳普医疗, 塞力医疗, and山河药辅 also reached the daily limit [3] Chip Sector - The domestic chip sector remained strong, with stocks like诚邦股份, 凯美特气, and常青股份 hitting the daily limit [6] - Reports indicated that Texas Instruments is raising prices for various analog devices by 30%, with some data converters seeing price increases of 100% [6] - The semiconductor industry is entering a new growth cycle driven by AI innovations and electric vehicle developments, which is expected to boost demand for high-performance analog chips [6][8] Glass Fiber Sector - The glass fiber sector saw significant gains, with companies like宏和科技, 中材科技, and山东玻纤 hitting the daily limit [9] - Market rumors suggest that NVIDIA's upcoming Rubin cabinet may utilize quartz cloth with lower dielectric constants, enhancing its application prospects in AI servers [9][10] Military Sector - The military sector showed mixed performance, with some stocks experiencing gains while others remained stable [11] Other Sectors - The electric power, PCB, and brain science sectors showed localized activity, while solid-state batteries and blockchain concepts faced declines [11]

Core Viewpoint - The A-share innovative drug sector experienced a significant surge on July 1, driven by favorable policy announcements from the National Medical Insurance Administration and the National Health Commission, which aim to support the high-quality development of innovative drugs [1][4]. Group 1: Market Performance - Frontier Biotech reached a 20% limit-up, with other companies like Guizhou BaiLing, Saily Medical, and AngliKang also hitting their limits [2]. - Notable stock performances included: - Frontier Biotech: 12.05 (+20.02%) - Kexing Pharmaceutical: 44.19 (+15.62%) - Yuyuan Pharmaceutical: 22.00 (+15.55%) - Shuyitai: 43.00 (+15.34%) - Rongchang Biotech: 68.39 (+13.04%) [3]. Group 2: Policy Support - The new measures encourage the use of medical insurance data for innovative drug research and development, enhancing collaboration among medical, insurance, and pharmaceutical sectors [4][6]. - The policy promotes the expansion of commercial health insurance investments in innovative drugs, establishing a new directory for innovative drugs that exceed basic insurance coverage [6]. - The National Medical Insurance Administration plans to streamline the application process for including drugs in both commercial and medical insurance directories, reducing the administrative burden on companies [6]. Group 3: Industry Outlook - The innovative drug sector is in a golden development phase, with over 20 first-class innovative drugs approved for market entry from January to May, marking a five-year high [7]. - Chinese pharmaceutical companies are accelerating their international expansion, with over 90 overseas licensing transactions expected in 2024, totaling over $50 billion [7]. - Significant licensing deals include: - 12.5 billion USD deal by 3SBio - 53.3 billion USD collaboration between CSPC and AstraZeneca - 42.3 billion USD agreement by Rongchang Biotech [7]. - Several biotech firms are increasing R&D investments through share placements, with funds directed towards global R&D pipelines [8]. Group 4: Investment Sentiment - Analysts agree on the sustainable growth potential of the innovative drug sector, emphasizing the "innovation + internationalization" trend as a core focus for the pharmaceutical industry [9]. - Investment opportunities are seen in the upstream pharmaceutical supply chain, advanced manufacturing, and healthcare services, with a focus on companies with strong growth potential and profitability [9].

Core Insights - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on the entire chain from research and development to payment systems [1] - The inclusion of innovative drug directories in commercial health insurance is expected to enhance the multi-tiered medical security system and provide economic support for the development of innovative drugs [1][2] - The stock market reacted positively, with significant gains in innovative drug concept stocks and ETFs, indicating strong investor interest and liquidity in this sector [1][2] Industry Developments - The establishment of a commercial insurance innovative drug directory marks a significant step in enhancing the role of commercial insurance in the multi-tiered medical security system, providing payment support for high-priced innovative drugs and medical devices [2] - The "18A" policy has catalyzed a wave of medical companies listing in Hong Kong, focusing on cutting-edge medical industry directions, which has attracted market attention and investment [2] Market Performance - The Hong Kong innovative drug ETF (513120) saw a rise of over 2%, with a trading volume of 4.1 billion yuan, leading the market in the pharmaceutical ETF category [1] - The latest scale of the Hong Kong innovative drug ETF reached 13.4 billion yuan, indicating its leading position in the market [1] - The innovative drug ETF (515120) also performed well, with a trading volume of 145 million yuan and a net inflow of nearly 200 million yuan over five consecutive days [1]

智通财经7月1日电，午后创新药概念持续走强，高位人气股昂利康3天2板创历史新高，此前贵州百灵、 塞力医疗涨停，科兴制药、舒泰神、热景生物、一品红涨超10%。消息面上，国家医保局、国家卫生健 康委印发《支持创新药高质量发展的若干措施》，其中提到，支持创新药进入基本医保药品目录和商业 健康保险创新药品目录；增设商业健康保险创新药品目录。 创新药概念持续走强 昂利康3天2板创历史新高 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-046 浙江昂利康制药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，浙江昂利康制药股份有限公司（以下简称"公 司"或"本公司"）通过回购专用证券账户（以下简称"回购专户"）持有的公司 股份不享有参与本次利润分配的权利。公司 2024 年年度权益分派方案为：以现 有总股本 201,728,186 股剔除公司回购专户中股份 5,619,700 股后的 196,108,486 股为基数，向全体股东每 10 股派 1.25 元人民币现金（含税），本次不进行公积 金转增股本、不送红股。公司本次现金分红的总金额=实际参与分配的总股本× 分配比例，即 24,513,560.75 元=196,108,486 股×0.125 元/股。 2、因公司回购专户上的股份不享有利润分配的权利，根据股票市值不变原 则，实施权益分派前后公司总股本保持不变，现金分红总 ...

Market Overview - The A-share market saw all three major indices rise in early trading, with the Shanghai Composite Index up 0.11%, the Shenzhen Component Index up 0.26%, and the ChiNext Index up 0.31% [1] - The total market turnover reached 100.26 billion yuan, an increase of 53.8 billion yuan compared to the previous day, with over 2900 stocks rising [1] Sector Performance - The military industry, diversified finance, solid-state battery, and CPO concept stocks led the gains, while innovative drugs, oil and gas extraction, and complete automobile sectors experienced declines [4] - The military sector saw a significant surge, with nearly 20 stocks hitting the daily limit, including Zhongguang Fanglei (300414) and Juyi Suoju (002342) [4] - The diversified finance sector continued its strong performance, with stocks like Ruida Futures (002961) and Hongye Futures (001236) also hitting the daily limit [4] - Solid-state battery concept stocks were active again, with Zhonglun New Materials (301565) hitting the daily limit and several others also performing well [4] Notable Stocks - The strongest performing stocks included: - 6 consecutive limit-up: Xingye Co., Ltd. (603928) [5] - 5 consecutive limit-up: Xintonglian (603022) [6] - 4 consecutive limit-up: Jida Zhengyuan (003029) [7] - 3 consecutive limit-up: Hongye Futures, Heli Tai (002217), and others [8] Hot Sectors - The military sector ranked as the top hot sector with 17 stocks hitting the daily limit and 10 stocks on consecutive limit-up streaks [9] - The new energy vehicle sector followed, with 15 stocks hitting the daily limit [10] - The Huawei concept sector also showed strength, with 13 stocks hitting the daily limit [11] Sector Insights - In the diversified finance sector, 40 institutions have been approved to provide virtual asset trading services, including Tianfeng Securities and others [14] - The military sector may see increased speculation due to geopolitical tensions, as comments from former President Trump suggest potential conflicts between Israel and Iran [15] - The solid-state battery sector is gaining attention with the launch of the vivo X Fold5, which features advanced battery technology [16]

证券代码：002940 证券简称：昂利康 公告编号：2025-045 近日，浙江昂利康制药股份有限公司（以下简称"公司"）控股子公司湖南 科瑞生物制药股份有限公司（以下简称"科瑞生物"）收到湖南省药品监督管理 局下发的《药品 GMP 符合性检查告知书》。现将有关情况公告如下： 一、GMP 检查相关信息 浙江昂利康制药股份有限公司 关于子公司通过药品 GMP 符合性检查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 由于国家政策、市场环境变化等因素影响，药品的生产、销售等具体情况存 在一定的不确定性，敬请广大投资者注意风险，理性投资。 特此公告。 | 企业名称 | 检查地址 | 检查范围及相关车间、生产线 | 检查时间 | | | 结论 | | --- | --- | --- | --- | --- | --- | --- | | 湖南科瑞 | 湖南省新 邵县酿溪 | 车间、 非那雄胺，101 车间、102 | | | | | | 生物制药 | | | 2025 年 4 月 | | 23 | | | | 镇大坪经 | 103 车间、精烘包（一）非那雄胺 ...